Individuel versus standard rFSH dosis til kontrolleret ovariel stimulation og intrauterin insemination Et prospektivt randomiseret multicenter studie

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-003481-34-DK

Enrollment

220

Registered

2006-07-13

Start date

2006-08-04

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovulatory women suffering from infertility

Interventions

Trade Name: Puregon Pharmaceutical Form: Injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ovulatory women suffering from undesired infertility Indication for controlled ovarian hyperstimulation, using standard rFSH doses, and intrauterine insemination. First cycle with gonadothrophine stimulation Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: More than 3 previous stimulated insemination cycles

Design outcomes

Primary

Measure	Time frame
Main Objective: To test if rFSH (Puregon) given in individual starting doses results in more patients muturing 2 or 3 follicles compared to a control group, who receive standard starting dose.;Secondary Objective: To test if fewer patients need a change in rFSH dose, after five days of stimulation, in the group that receive individual starting doses compared to the group that receive standard starting dose. ;Primary end point(s): Number of mature follicles	—

Measure

Time frame

Main Objective: To test if rFSH (Puregon) given in individual starting doses results in more patients muturing 2 or 3 follicles compared to a control group, who receive standard starting dose.;Secondary Objective: To test if fewer patients need a change in rFSH dose, after five days of stimulation, in the group that receive individual starting doses compared to the group that receive standard starting dose. ;Primary end point(s): Number of mature follicles

—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026